CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

被引：2
|
作者：
Cutri-French, Clare [1 ]
Nasioudis, Dimitrios [2 ]
George, Erin [3 ]
Tanyi, Janos L. [2 ]
机构：
[1] Univ Penn Hlth Syst, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[2] Univ Penn Hlth Syst, Div Gynecol Oncol, Philadelphia, PA 19104 USA
[3] Richard M Schulze Family Fdn Outpatient Ctr, Moffitt Canc Ctr, McKinley Campus,10920 McKinley Dr, Tampa, FL 33612 USA
来源：
DIAGNOSTICS | 2024年 / 14卷 / 08期
关键词：
ovarian cancer; CAR-T therapy; target antigens; mesothelin; CHIMERIC ANTIGEN RECEPTORS; PHASE-I; MESOTHELIN; IMMUNOTHERAPY; EXPRESSION; TARGET; GENERATION; EFFICACY; BINDING; PROTEIN;
D O I：
10.3390/diagnostics14080819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of hematologic malignancies has led to the investigation of their potential in the treatment of solid tumors, including ovarian cancer. While the immunosuppressive microenvironment of ovarian cancer has been a barrier in their implementation, several early phase clinical trials are currently evaluating CAR-T cell therapies targeting mesothelin, folate receptor a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated and "on-target, off-tumor" toxicities, while most common adverse events include cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), and neurotoxicity. In the present review, we summarize the current status of CAR-T therapy in ovarian cancer and discuss future directions.
引用
收藏
页数：17
相关论文
共 50 条
  • [1] CAR-T cell therapy: Where are we now, and where are we heading?
    Wang, Jia-Yi
    Wang, Liang
    [J]. BLOOD SCIENCE, 2023, 5 (04): : 237 - 248
  • [2] CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan, Aalia N.
    Asija, Sweety
    Pendhari, Juber
    Purwar, Rahul
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 6 - 18
  • [3] CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
    Fischer, Luise
    Grieb, Nora
    Platzbecker, Uwe
    Vucinic, Vladan
    Merz, Maximilian
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, : 19 - 27
  • [4] CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
    Ghosh, Arnab
    Mailankody, Sham
    Giralt, Sergio A.
    Landgren, C. Ola
    Smith, Eric L.
    Brentjens, Renier J.
    [J]. LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2056 - 2067
  • [5] CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
    Zhang, Xi-Wen
    Wu, Yi-Shi
    Xu, Tian-Min
    Cui, Man-Hua
    [J]. BIOMOLECULES, 2023, 13 (03)
  • [6] CAR-T cell therapy in ovarian cancer: from the bench to the bedside
    Zhu, Xinxin
    Cai, Han
    Zhao, Ling
    Ning, Li
    Lang, Jinghe
    [J]. ONCOTARGET, 2017, 8 (38) : 64607 - 64621
  • [7] Prediction of therapy response in ovarian cancer: Where are we now?
    El Bairi, Khalid
    Amrani, Mariam
    Kandhro, Abdul Hafeez
    Afqir, Said
    [J]. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2017, 54 (04) : 233 - 266
  • [8] CAR-T Cell Therapy
    Ahmad, Aamir
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12)
  • [9] CAR-T cell therapy
    San Segundo, Lucrecia Yanez
    [J]. MEDICINA CLINICA, 2021, 156 (03): : 123 - 125
  • [10] CAR-T Cell Therapy: From the Shop to Cancer Therapy
    Uscanga-Palomeque, Ashanti Concepcion
    Chavez-Escamilla, Ana Karina
    Alvizo-Baez, Cynthia Aracely
    Saavedra-Alonso, Santiago
    Terrazas-Armendariz, Luis Daniel
    Tamez-Guerra, Reyes S.
    Rodriguez-Padilla, Cristina
    Alcocer-Gonzalez, Juan Manuel
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (21)
12345